Evidence map›Paper›PMID 23126554›Full record

ArticleAlcoholism, clinical and experimental research2013

Pharmacological characterization of the 20% alcohol intermittent access model in Sardinian alcohol-preferring rats: a model of binge-like drinking.

Valentina Sabino, Jina Kwak, Kenner C Rice, Pietro Cottone

Open access · greenAbstract read
In one paragraph

Article in Alcoholism, clinical and experimental research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Medications for alcohol use disorders: An overview.Pharmacology & therapeutics · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Valentina SabinoLaboratory of Addictive Disorders, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA. vsabino@bu.edu
Jina Kwak
Kenner C Rice
Pietro Cottone
Boston University · USNational Institute on Drug Abuse · US

Funding

Role of Neuropeptides in AnxietyR01MH093650 · NIMH · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SABINO, VALENTINA · 2012 to 2016
$2.0M
Role of the Endocannabinoid System in Compulsive EatingR01MH091945 · NIMH · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COTTONE, PIETRO · 2010 to 2014
$2.0M
Neurobiology of compulsive eating.R01DA030425 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COTTONE, PIETRO · 2011 to 2015
$1.6M
Medicinal Chemistry in the Study of Alcohol AbuseZIADA000531 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2016
$1.1M
The dark side of preferred food addiction: role of CRF systemsR00DA023680 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COTTONE, PIETRO · 2009 to 2011
$735k
Role of sigma receptors in ethanol reinforcementR00AA016731 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SABINO, VALENTINA · 2009 to 2011
$732k
The dark side of preferred food addiction: role of CRF systemsK99DA023680 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI COTTONE, PIETRO · 2007 to 2008
$179k
Role of sigma receptors in ethanol reinforcementK99AA016731 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI SABINO, VALENTINA · 2007 to 2008
$153k
Intramural NIH HHSNIAAA NIH HHS AA016731NIAAA NIH HHS K99 AA016731NIAAA NIH HHS R00 AA016731NIDA NIH HHS DA023680NIDA NIH HHS DA030425NIDA NIH HHS K99 DA023680NIDA NIH HHS R00 DA023680NIDA NIH HHS R01 DA030425NIMH NIH HHS MH091944NIMH NIH HHS MH091945NIMH NIH HHS R01 MH091945NIMH NIH HHS R01 MH093650
6 · The paper itself

Abstract

backgroundBinge drinking is defined as a pattern of alcohol drinking that brings blood alcohol levels to 80 mg/dl or above. In this study, we pharmacologically characterized the intermittent access to 20% ethanol (EtOH) model (Wise, Psychopharmacologia 1973;29:203) in Sardinian alcohol-preferring (sP) rats to determine to which of the compounds known to reduce drinking in specific animal models this binge-like drinking was sensitive to.

methodsAdult male sP rats were divided into 2 groups and allowed to drink either 20% v/v alcohol or water for 24 hours on alternate days (Monday, Wednesday, and Friday) or 10% v/v alcohol and water for 24 hours every day. After stabilization of their intake, both groups were administered 3 pharmacological agents with different mechanisms of action, naltrexone-an opioid receptor antagonist, SCH 39166-a dopamine D1 receptor antagonist, and R121919-a Corticotropin-Releasing Factor 1 (CRF1 ) receptor antagonist, and their effects on alcohol and water intake were determined.

resultsIntermittent 20% alcohol ("Wise") procedure in sP rats led to binge-like drinking. Alcohol drinking was suppressed by naltrexone and by SCH 39166, but not by R121919. Finally, naltrexone was more potent in reducing alcohol drinking in the intermittent 20% binge-drinking group than in the 10% continuous access drinking group.

conclusionsThe Wise procedure in sP rats induces binge-like drinking, which appears opioid- and dopamine-receptor mediated; the CRF1 system, on the other hand, does not appear to be involved. In addition, our results suggest that naltrexone is particularly effective in reducing binge drinking. Such different pharmacological responses may apply to subtypes of alcoholic patients who differ in their motivation to drink, and may eventually contribute to treatment response.

Indexed as

Disease Models, AnimalAlcohol DrinkingAnimalsBenzazepinesBinge DrinkingChoice BehaviorCRF Receptor, Type 1Dopamine AntagonistsEthanolMaleNaltrexoneNarcotic AntagonistsPyrimidinesRatsReceptors, Corticotropin-Releasing HormoneSelf AdministrationBenzazepinesCRF Receptor, Type 1Dopamine AntagonistsecopipamEthanolNaltrexoneNarcotic AntagonistsPyrimidinesR 121919Receptors, Corticotropin-Releasing Hormone

Identifiers

PMID23126554
PMCPMC3567206
OpenAlexW2020443789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.